Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 725 of 2228 entries
View as:

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT03793621 Org: User:
Start: 01/21/19 End: 04/26/19 Due: 04/26/20

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Phase: N/A Priority: Normal
NCT ID: NCT01897532 Org: User:
Start: 07/10/13 End: 01/18/18 Due: 01/18/19

Safety Tolerability and Pharmacokinetic of BI 411034

Phase: N/A Priority: Normal
NCT ID: NCT01581684 Org: User:
Start: 04/01/12 End: 08/01/12 Due: 08/01/13

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Phase: N/A Priority: Normal
NCT ID: NCT01343888 Org: User:
Start: 04/30/11 End: 03/31/14 Due: 03/31/15

Antihypertensive Medications and the Risk of Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT02248896 Org: User:
Start: 01/31/10 End: - Due: -

Tiotropium / Respimat One Year Study in COPD.

Phase: N/A Priority: Normal
NCT ID: NCT00387088 Org: User:
Start: 09/30/06 End: - Due: -

To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02706925 Org: User:
Start: 03/22/16 End: 06/13/16 Due: 06/13/17

Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT02850978 Org: User:
Start: 08/23/16 End: 11/30/18 Due: 11/30/19

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Phase: N/A Priority: Normal
NCT ID: NCT06321302 Org: User:
Start: 05/15/24 End: 11/11/26 Due: 11/11/27

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Phase: N/A Priority: Normal
NCT ID: NCT06238622 Org: User:
Start: 09/24/24 End: 05/05/27 Due: 05/05/28

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

Phase: N/A Priority: Normal
NCT ID: NCT01505894 Org: User:
Start: 01/01/12 End: 07/01/12 Due: 07/01/13

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT06791122 Org: User:
Start: 01/23/25 End: 02/15/27 Due: 02/15/28

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT02624492 Org: User:
Start: 01/28/16 End: 03/16/18 Due: 03/16/19

TARA Working Prototype [Version 2]: Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT04320524 Org: User:
Start: 02/17/21 End: 09/06/21 Due: 09/06/22

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Phase: N/A Priority: Normal
NCT ID: NCT01644734 Org: User:
Start: 11/30/11 End: 03/31/13 Due: 03/31/14

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06151574 Org: User:
Start: 02/09/24 End: 01/28/28 Due: 01/28/29

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Phase: N/A Priority: Normal
NCT ID: NCT06531824 Org: User:
Start: 08/13/24 End: 08/30/28 Due: 08/30/29

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Phase: N/A Priority: Normal
NCT ID: NCT06232252 Org: User:
Start: 05/06/24 End: 04/29/25 Due: 04/29/26

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Phase: N/A Priority: Normal
NCT ID: NCT06806852 Org: User:
Start: 05/14/25 End: 03/30/28 Due: 03/30/29

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02268604 Org: User:
Start: 10/31/10 End: - Due: -

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

Phase: N/A Priority: Normal
NCT ID: NCT00472199 Org: User:
Start: 05/31/07 End: - Due: -

Real World Data on Management of Male LUTS

Phase: N/A Priority: Normal
NCT ID: NCT03075449 Org: User:
Start: 05/19/16 End: 12/21/16 Due: 12/21/17

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02177305 Org: User:
Start: 10/31/98 End: - Due: -

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02850965 Org: User:
Start: 08/17/16 End: 01/17/18 Due: 01/17/19

PMS of Trazenta on the Long-term Use as Add-on Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01904383 Org: User:
Start: 07/01/13 End: 10/04/18 Due: 10/04/19